- Home
- CRVO
CRVO
CervoMed Inc.
as 12-17-2024 4:00pm EST
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 98.3M | IPO Year: | N/A |
| Target Price: | $38.75 | AVG Volume (30 days): | 922.0K |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.80 - $26.38 | Next Earning Date: | 11-12-2024 |
| Revenue: | $10,066,550 | Revenue Growth: | 116.29% |
| Revenue Growth (this year): | 34.17% | Revenue Growth (next year): | -36.16% |
Latest CervoMed Inc. News
CRVO Breaking Stock News: Dive into CRVO Ticker-Specific Updates for Smart Investing
TipRanks
6 days ago
CervoMed price target lowered to $4 from $45 at Roth MKM
GlobeNewswire
6 days ago
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
7 days ago
Morgan Stanley Downgrades CervoMed to Underweight From Overweight
TipRanks
7 days ago
CervoMed announces RewinD-LB Phase 2b did not meet primary endpoint
MT Newswires
7 days ago
Chardan Downgrades CervoMed to Neutral From Buy, Withdraws $55 Price Target
MT Newswires
8 days ago
Top Midday Decliners
Benzinga
8 days ago
CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets
MT Newswires
8 days ago
Brookline Downgrades CervoMed to Hold From Buy; Shares Plunge
Compare CRVO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRVO CervoMed Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.